Bli medlem
Bli medlem

Du är här


RaySearch Laboratories: Share conversion and changes in major shareholders's voting power in RaySearch Laboratories AB (publ)

On 5 December 2016, 1,567,089 Class A shares were converted to Class B
shares, at the request of a shareholder, Erik Hedlund. The total
number of votes in RaySearch thereafter amounts to 112,537,548 votes.
The total number of registered shares in RaySearch amounts to
34,282,773 shares, of which 8,694,975 are Class A shares and
25,587,798 are Class B shares. The share conversion has led to an
increased voting power for major shareholder Johan Löf and a
decreased voting power for major shareholder Erik Hedlund.

According to RaySearch Laboratories AB's (publ) Articles of
Association, owners of Class A shares have the right to have such
shares converted to Class B shares. A conversion reduces the number
of votes in the company and also changes the voting power for
shareholders. As a result of this share conversion, Johan Löf's
voting power has increased above 50% and he now controls
approximately 56,0% of the votes in RaySearch. At the same time, Erik
Hedlund's voting power has decreased below 10% through the share
conversion and he now controls approximately 1,5% of the votes in

When a share conversion has been carried out and when the voting power
has changed as described herein, RaySearch is obligated by law to
disclose information on the changes occurred by the conversion.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that
develops innovative software solutions for improved radiation therapy
of cancer. RaySearch develops and markets the RayStation treatment
planning system to clinics all over the world and distributes the
products through licensing agreements with leading medical technology
companies. The company is also developing the next-generation
oncology information system, RayCare, which comprises a new product
area for RaySearch, and will be launched in 2017. RaySearch's
software is currently used by over 2,600 clinics in more than 65
countries. The company was founded in 2000 as a spin-off from the
Karolinska Institute in Stockholm and the share has been listed on
Nasdaq Stockholm since November 2003.

For more information about RaySearch, visit

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00

RaySearch discloses the information provided herein pursuant to the
Securities Market Act and/or the Financial Instruments Trading Act.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.